Read by QxMD icon Read

Journal of Prevention of Alzheimer's Disease

K Duff, D B Hammers, B C A Dalley, K R Suhrie, T J Atkinson, K M Rasmussen, K P Horn, B E Beardmore, L D Burrell, N L Foster, J M Hoffman
BACKGROUND: Practice effects, which are improvements in cognitive test scores due to repeated exposure to testing materials, may provide information about Alzheimer's disease pathology, which could be useful for clinical trials enrichment. OBJECTIVES: The current study sought to add to the limited literature on short-term practice effects on cognitive tests and their relationship to amyloid deposition on neuroimaging. PARTICIPANTS: Twenty-seven, non-demented older adults (9 cognitively intact, 18 with mild cognitive impairment) received amyloid imaging with 18F-Flutemetamol, and two cognitive testing sessions across one week to determine practice effects...
2017: Journal of Prevention of Alzheimer's Disease
X Zhang, F A Schmitt, A M Caban-Holt, X Ding, R J Kryscio, E Abner
BACKGROUND: Subjective memory complaints (SMCs) are associated with increased risk of dementia in older adults, but the role of comorbidities in modifying this risk is unknown. OBJECTIVES: To assess whether comorbidities modify estimated dementia risk based on SMCs. DESIGN: The Prevention of Alzheimer's Disease with Vitamin E and Selenium Study (PREADVISE) was designed as an ancillary study to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized, multi-center prostate cancer prevention trial with sites in the Unites States, Puerto Rico, and Canada...
2017: Journal of Prevention of Alzheimer's Disease
A M Fosnacht, S Patel, C Yucus, A Pham, E Rasmussen, R Frigerio, S Walters, D Maraganore
BACKGROUND: Alzheimer's disease and aging brain disorders are progressive, often fatal neurodegenerative diseases. Successful aging, modern lifestyles and behaviors have combined to result in an expected epidemic. Risks for these diseases include genetic, medical, and lifestyle factors; over 20 modifiable risks have been reported. OBJECTIVES: We aim to primarily prevent Alzheimer's disease and related disorders through electronic medical record (EMR)-based screening, risk assessments, interventions, and surveillance...
2017: Journal of Prevention of Alzheimer's Disease
H Hampel, S E O'Bryant, J I Castrillo, C Ritchie, K Rojkova, K Broich, N Benda, R Nisticò, R A Frank, B Dubois, V Escott-Price, S Lista
During this decade, breakthrough conceptual shifts have commenced to emerge in the field of Alzheimer's disease (AD) recognizing risk factors and the non-linear dynamic continuum of complex pathophysiologies amongst a wide dimensional spectrum of multi-factorial brain proteinopathies/neurodegenerative diseases. As is the case in most fields of medicine, substantial advancements in detecting, treating and preventing AD will likely evolve from the generation and implementation of a systematic precision medicine strategy...
December 2016: Journal of Prevention of Alzheimer's Disease
E T Reas, G A Laughlin, D Kritz-Silverstein, E Barrett-Connor, L K McEvoy
BACKGROUND: Evidence suggests that moderate alcohol consumption may protect against cognitive decline and dementia. However, uncertainty remains over the patterns of drinking that are most beneficial. OBJECTIVE: To examine associations between amount and frequency of alcohol consumption with multiple domains of cognitive function in a well-characterized cohort of older community-dwelling adults in southern California. DESIGN: Observational, cross-sectional cohort study...
September 2016: Journal of Prevention of Alzheimer's Disease
J Cummings, P Aisen, R Barton, J Bork, R Doody, J Dwyer, J C Egan, H Feldman, D Lappin, L Truyen, S Salloway, R Sperling, G Vradenburg
Alzheimer's disease (AD) drug development is costly, time-consuming, and inefficient. Trial site functions, trial design, and patient recruitment for trials all require improvement. The Global Alzheimer Platform (GAP) was initiated in response to these challenges. Four GAP work streams evolved in the US to address different trial challenges: 1) registry-to-cohort web-based recruitment; 2) clinical trial site activation and site network construction (GAP-NET); 3) adaptive proof-of-concept clinical trial design; and 4) finance and fund raising...
June 2016: Journal of Prevention of Alzheimer's Disease
R J Kryscio, E L Abner, P T Nelson, D Bennett, J Schneider, L Yu, L S Hemmy, K O Lim, K Masaki, N Cairns, C Xiong, R Woltjer, H H Dodge, S Tyas, D W Fardo, W Lou, L Wan, F A Schmitt
BACKGROUND: Cerebral vascular pathology may contribute to cognitive decline experienced by some elderly near death. Given evidence for mixed neuropathologies in advanced age, preventing or reducing cerebrovascular burden in late life may be beneficial. OBJECTIVE: To correlate measures of cerebral vascular pathology with cognitive trajectories. SETTING: Observational study. PARTICIPANTS: A cohort of 2,274 individuals who came to autopsy at a mean age of 89...
June 2016: Journal of Prevention of Alzheimer's Disease
J Delrieu, S Andrieu, M Pahor, C Cantet, M Cesari, P J Ousset, T Voisin, B Fougère, S Gillette, I Carrie, B Vellas
OBJECTIVES: An international group proposed the existence of "cognitive frailty", a condition defined by simultaneous presence of physical frailty and cognitive impairment in the absence of dementia. The objective was to compare the neuropsychological profiles in subgroups of elders differentiated across their physical frailty (Fried phenotype) and cognitive status (Clinical Dementia Rating score) to characterize the "cognitive frailty" entity. METHOD: We studied baseline characteristics of 1,617 subjects enrolled in Multidomain Alzheimer Disease Preventive Trial (MAPT)...
June 2016: Journal of Prevention of Alzheimer's Disease
R J Kryscio, E L Abner, G A Jicha, P T Nelson, C D Smith, L J Van Eldik, W Lou, D W Fardo, G E Cooper, F A Schmitt
BACKGROUND: Subjective memory complaints are common in aged persons, indicating an increased, but incompletely understood, risk for dementia. OBJECTIVE: To compare cognitive trajectories and autopsy results of individuals with subjective complaints after stratifying by whether a subsequent clinical dementia occurred. DESIGN: Observational study. SETTING: University of Kentucky cohort with yearly longitudinal assessments and eventual autopsies...
March 2016: Journal of Prevention of Alzheimer's Disease
Dorene M Rentz, Maria Dekhtyar, Julia Sherman, Samantha Burnham, Deborah Blacker, Sarah L Aghjayan, Kathryn V Papp, Rebecca E Amariglio, Adrian Schembri, Tanya Chenhall, Paul Maruff, Paul Aisen, Bradley T Hyman, Reisa A Sperling
BACKGROUND: Technological advances now make it feasible to administer cognitive assessments at-home on mobile and touch-screen devices such as an iPad or tablet computer. Validation of these techniques is necessary to assess their utility in clinical trials. OBJECTIVES: We used a Computerized Cognitive Composite for Preclinical Alzheimer's Disease (C3-PAD) developed for iPad 1) to determine the feasibility of performing the C3-PAD at home by older individuals without the presence of a trained psychometrician; 2) to explore the reliability of in-clinic compared to at-home C3-PAD performance and 3) to examine the comparability of C3-PAD performance to standardized neuropsychological tests...
March 2016: Journal of Prevention of Alzheimer's Disease
P J Smith, J A Blumenthal
Cognitive decline is an increasingly important public health problem, with more than 100 million adults worldwide projected to develop dementia by 2050. Accordingly, there has been an increased interest in preventive strategies that diminish this risk. It has been recognized that lifestyle factors including dietary patterns, may be important in the prevention of cognitive decline and dementia in later life. Several dietary components have been examined, including antioxidants, fatty acids, and B vitamins. In addition, whole dietary eating plans, including the Mediterranean diet (MeDi), and the Dietary Approaches to Stop Hypertension (DASH) diet, with and without weight loss, have become areas of increasing interest...
March 2016: Journal of Prevention of Alzheimer's Disease
J-M Leoutsakos, A L Gross, R N Jones, M S Albert, J C S Breitner
BACKGROUND: Alzheimer's disease (AD) prevention research requires methods for measurement of disease progression not yet revealed by symptoms. Preferably, such measurement should encompass multiple disease markers. OBJECTIVES: Evaluate an item response theory (IRT) model-based latent variable Alzheimer Progression Score (APS) that uses multi-modal disease markers to estimate pre-clinical disease progression. DESIGN: Estimate APS scores in the BIOCARD observational study, and in the parallel PREVENT-AD Cohort and its sister INTREPAD placebo-controlled prevention trial...
2016: Journal of Prevention of Alzheimer's Disease
A M Wessels, E R Siemers, P Yu, S W Andersen, K C Holdridge, J R Sims, K Sundell, Y Stern, D M Rentz, B Dubois, R W Jones, J Cummings, P S Aisen
It is generally recognized that more sensitive instruments for the earliest stages of Alzheimer's disease (AD) are needed. The integrated Alzheimer's Disease Rating Scale (iADRS) combines scores from 2 widely accepted measures, the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living (ADCS-iADL). Disease progression and treatment differences as measured by the iADRS were analyzed using data from solanezumab EXPEDITION, EXPEDITION2, and EXPEDITION-EXT Studies; semagacestat IDENTITY Study; and donepezil ADCS - mild cognitive impairment (ADCS-MCI) Study...
December 1, 2015: Journal of Prevention of Alzheimer's Disease
Gad A Marshall, Maria Dekhtyar, Jonathan M Bruno, Kamal Jethwani, Rebecca E Amariglio, Keith A Johnson, Reisa A Sperling, Dorene M Rentz
BACKGROUND: Impairment in activities of daily living is a major burden for Alzheimer's disease dementia patients and caregivers. Multiple subjective scales and a few performance-based instruments have been validated and proven to be reliable in measuring instrumental activities of daily living in Alzheimer's disease dementia but less so in amnestic mild cognitive impairment and preclinical Alzheimer's disease. OBJECTIVE: To validate the Harvard Automated Phone Task, a new performance-based activities of daily living test for early Alzheimer's disease, which assesses high level tasks that challenge seniors in daily life...
December 2015: Journal of Prevention of Alzheimer's Disease
C G Lyketsos
No abstract text is available yet for this article.
September 2015: Journal of Prevention of Alzheimer's Disease
M Soto, S Abushakra, J Cummings, J Siffert, P Robert, B Vellas, C G Lyketsos
The management of neuropsychiatric symptoms (NPS) such as agitation and aggression is a major priority in caring for people with Alzheimer's disease (AD). Agitation and aggression (A/A) are among the most disruptive symptoms, and given their impact, they are increasingly an important target for development of effective treatments. Considerable progress has been made in the last years with a growing number of randomized controlled trials (RCTs) of drugs for NPS. The limited benefits reported in some RCTs may be accounted for by the absence of a biological link of the tested molecule to NPS and also by key methodological issues...
September 2015: Journal of Prevention of Alzheimer's Disease
M S Rafii
No abstract text is available yet for this article.
June 2015: Journal of Prevention of Alzheimer's Disease
S Hendrix, N Ellison, S Stanworth, L Tierney, F Mattner, W Schmidt, B Dubois, A Schneeberger
BACKGROUND: Optimized scales and composite outcomes have been proposed as a way to more accurately measure Alzheimer's disease related decline. AFFITOPE® AD02, is an amyloid-beta (Aβ)-targeting vaccine to elicit anti-Aβ antibodies. IMM-AD04, commonly known as Alum, originally designated as a control agent, appeared to have disease-modifying activity in a multicenter, parallel group phase II study in early AD patients. OBJECTIVES: To develop adapted outcomes for cognition, function and a composite scale with improved sensitivity to decline and treatment effects in early AD (mild plus prodromal AD) based on historical data and to assess these adapted outcomes in this phase II study...
June 2015: Journal of Prevention of Alzheimer's Disease
A S Atkins, I Stroescu, N B Spagnola, V G Davis, T D Patterson, M Narasimhan, P D Harvey, R S E Keefe
Clinical trials for primary prevention and early intervention in preclinical AD require measures of functional capacity with improved sensitivity to deficits in healthier, non-demented individuals. To this end, the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) was developed as a direct performance-based assessment of functional capacity that is sensitive to changes in function across multiple populations. Using a realistic virtual reality environment, the VRFCAT assesses a subject's ability to complete instrumental activities associated with a shopping trip...
June 2015: Journal of Prevention of Alzheimer's Disease
B Vellas, R Bateman, K Blennow, G Frisoni, K Johnson, R Katz, J Langbaum, D Marson, R Sperling, A Wessels, S Salloway, R Doody, P Aisen
For Alzheimer's disease treatment trials that focus on the pre-dementia stage of disease, outcome measures are needed that will enable assessment of disease progression in patients who are clinically normal. The EU/US CTAD Task Force, an international collaboration of investigators from industry, academia, non-profit foundations, and regulatory agencies, met in Philadelphia, Pennsylvania, USA, on November 19, 2014 to discuss existing and novel outcome assessments that may be useful in pre-dementia trials. Composite measures that assess changes in episodic memory, executive function, global cognition, and global function have recently been developed by a number of groups and appear to be sensitive at this stage...
June 2015: Journal of Prevention of Alzheimer's Disease
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"